Previous Article | Next Article 
Molecular and Cellular Biology, August 2006, p. 5895-5907, Vol. 26, No. 15
0270-7306/06/$08.00+0 doi:10.1128/MCB.00552-06
Copyright © 2006, American Society for Microbiology. All Rights Reserved.
Proteasomal Inhibition Attenuates Transcriptional Activity of Hypoxia-Inducible Factor 1 (HIF-1) via Specific Effect on the HIF-1
C-Terminal Activation Domain
Stefan Kaluz ,
,
*
Milota Kaluzová,
,
and
Eric J. Stanbridge
Department of Microbiology and Molecular Genetics, College of Medicine, University of California at Irvine, Irvine, California 92717
Received 29 March 2006/
Returned for modification 2 May 2006/
Accepted 21 May 2006
The ubiquitin-proteasome pathway (UPP) is involved in regulation of multiple cellular processes. Hypoxia-inducible factor 1
(HIF-1
) is a prototypic target of the UPP and, as such, is stabilized under conditions of proteasomal inhibition. Using carbonic anhydrase IX (CAIX) and vascular endothelial growth factor (VEGF) expression as paradigmatic markers of HIF-1 activity, we found that proteasomal inhibitors (PI) abrogated hypoxia-induced CAIX expression in all cell lines tested and VEGF expression in two out of three. Mapping of the inhibitory effect identified the C-terminal activation domain (CAD) of HIF-1
as the primary target of PI. PI specifically inhibited the HIF-1
CAD despite activating the HIF-1
coactivator p300 and another p300 cysteine/histidine-rich domain 1-dependent transcription factor, STAT-2. Coimmunoprecipitation and glutathione S-transferase pull downs indicated that PI does not disrupt interactions between HIF-1
and p300. Mutational analysis failed to confirm involvement of sites of known or putative posttranslational modifications in regulation of HIF-1
CAD function by PI. Our data provide evidence for the counterintuitive hypothesis that inhibition of HIF-1 function could be responsible for at least some of the antitumor effects of proteasomal inhibition. Further studies of the mechanism of the PI-induced attenuation of HIF-1
will provide important, potentially novel insight into regulation of HIF-1 activity and possibly identify new targets for HIF-directed therapy.
* Corresponding author. Mailing address: Department of Microbiology and Molecular Genetics, Medical Science I B210, University of California at Irvine, College of Medicine, Irvine, CA 92697-4025. Phone: (949) 824-5259. Fax: (949) 824-8598. E-mail:
skaluz{at}uci.edu.
These two authors contributed equally to this work.
Permanent address: Institute of Virology, Slovak Academy of Sciences, Bratislava, Slovak Republic.
Molecular and Cellular Biology, August 2006, p. 5895-5907, Vol. 26, No. 15
0270-7306/06/$08.00+0 doi:10.1128/MCB.00552-06
Copyright © 2006, American Society for Microbiology. All Rights Reserved.
This article has been cited by other articles:
-
Simmons, S. O., Fan, C.-Y., Ramabhadran, R.
(2009). Cellular Stress Response Pathway System as a Sentinel Ensemble in Toxicological Screening. Toxicol Sci
111: 202-225
[Abstract]
[Full Text]
-
Hu, Y., Kirito, K., Yoshida, K., Mitsumori, T., Nakajima, K., Nozaki, Y., Hamanaka, S., Nagashima, T., Kunitama, M., Sakoe, K., Komatsu, N.
(2009). Inhibition of hypoxia-inducible factor-1 function enhances the sensitivity of multiple myeloma cells to melphalan. Molecular Cancer Therapeutics
8: 2329-2338
[Abstract]
[Full Text]
-
Zhu, K., Chan, W., Heymach, J., Wilkinson, M., McConkey, D. J.
(2009). Control of HIF-1{alpha} Expression by eIF2{alpha} Phosphorylation-Mediated Translational Repression. Cancer Res.
69: 1836-1843
[Abstract]
[Full Text]
-
Li, S. H., Shin, D. H., Chun, Y.-S., Lee, M. K., Kim, M.-S., Park, J.-W.
(2008). A novel mode of action of YC-1 in HIF inhibition: stimulation of FIH-dependent p300 dissociation from HIF-1{alpha}. Molecular Cancer Therapeutics
7: 3729-3738
[Abstract]
[Full Text]
-
Kaluz, S., Kaluzova, M., Stanbridge, E. J.
(2008). Comment on the role of FIH in the inhibitory effect of bortezomib on hypoxia-inducible factor-1. Blood
111: 5258-5259
[Full Text]
-
Shin, D. H., Chun, Y.-S., Lee, D. S., Huang, L. E., Park, J.-W.
(2008). Bortezomib inhibits tumor adaptation to hypoxia by stimulating the FIH-mediated repression of hypoxia-inducible factor-1. Blood
111: 3131-3136
[Abstract]
[Full Text]
-
Yu, P., Kodadek, T.
(2007). Dynamics of the Hypoxia-inducible Factor-1-Vascular Endothelial Growth Factor Promoter Complex. J. Biol. Chem.
282: 35035-35045
[Abstract]
[Full Text]
-
Birle, D. C., Hedley, D. W.
(2007). Suppression of the Hypoxia-Inducible Factor-1 Response in Cervical Carcinoma Xenografts by Proteasome Inhibitors. Cancer Res.
67: 1735-1743
[Abstract]
[Full Text]
-
Papageorgiou, A., Kamat, A., Benedict, W. F., Dinney, C., McConkey, D. J.
(2006). Combination therapy with IFN-{alpha} plus bortezomib induces apoptosis and inhibits angiogenesis in human bladder cancer cells. Molecular Cancer Therapeutics
5: 3032-3041
[Abstract]
[Full Text]